Cardiovascular and Renal Complications in Patients with Resistant Hypertension

Current Hypertension Reports

Volumn 16, Issue 9, 2014, Pages 1-12

  Muxfeldt, Elizabeth S ^a,b   de Souza, Fabio ^a   Margallo, Victor S ^a   Salles, Gil F ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b NONE   (Brazil)

Author keywords

Cardiovascular complications; Prognosis; Renal complications; Resistant hypertension

Indexed keywords

BLOOD PRESSURE; COMPLICATION; HEALTH; HUMAN; HYPERTENSION; KIDNEY DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGY; PREVALENCE; PROGNOSIS; RISK FACTOR;

BLOOD PRESSURE; GLOBAL HEALTH; HUMANS; HYPERTENSION; KIDNEY DISEASES; PREVALENCE; PROGNOSIS; RISK FACTORS;

EID: 84939872770     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0471-7     Document Type: Review

References (56)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. Hypertension. 2003;42:1206–52.
2. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. Task Force Members. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.
3. Moser M, Roccella EJ. The Treatment of Hypertension: A Remarkable Success Story. J Clin Hypertens (Greenwich). 2013;15:88–91.
4. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global Burden of Hypertension: Analysis of Worldwide Data. Lancet. 2005;365:217–23.
5. Lim SS, Vos T, Flaxman AD, et al. A Comparative Risk Assessment of Burden of Disease and Injury Attributable to 67 Risk Factors and Risk Factor Clusters in 21 Regions, 1990-2010: A Systematic Analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224–60.
6. Calhoun DA, Jones D, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment. A Scientific Statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–19. The unique comprehensive guideline on resistant hypertension approach.
7. de la Sierra A, Banegas JR, Oliveras A, Gorostidi M, Segura J, de la Cruz JJ, et al. Clinical Differences Between Resistant Hypertensives and Patients Treated and Controlled with Three or Less Drugs. J Hypertens. 2012;30:1211–6.
8. Muxfeldt ES, Salles GF. Pulse Pressure or Dipping Pattern: Which one is a Better Cardiovascular Risk Marker in Resistant Hypertension? J Hypertens. 2008;26:878–84.
9. Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, et al. Obstructive Sleep Apnea: The Most Common Secondary Cause of Hypertension Associated with Resistant Hypertension. Hypertension. 2011;58:811–7.
10. Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlöf B, Poulter NR. ASCOT Investigators. Baseline Predictors of Resistant Hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a Risk Score to Identify Those at High-Risk. J Hypertens. 2011;29:2004–13.
11. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, Fusi V, et al. High Prevalence of Cardiac and Extra- Cardiac Target Organ Damage in Refractory Hypertension. J Hypertens. 2001;19:2063–70.
12. Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. Twenty-Four Hour Ambulatory Blood Pressure Monitoring Pattern of Resistant Hypertension. Blood Press Monit. 2003;8:181–5.
13. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM, et al. Cardiovascular Outcome in Treated Hypertensive Patients with Responder, Masked, False Resistant, and True Resistant Hypertension. Am J Hypertens. 2005;18:1422–8.
14. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and Prognosis of Resistant Hypertension in Hypertensive Patients. Circulation. 2012;125:1635–42.
15. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic Influence of Office and Ambulatory Blood Pressures in Resistant Hypertension. Arch Intern Med. 2008;168:2340–6. Higher ambulatory blood pressure are important predictors of cardiovascular morbidity and mortality in a large cohort of RHT patients, but office BP has no prognostic importance.
16. Acelajado MC, Pisoni R, Dudenbostel T, Dell’Italia LJ, Cartmill F, Zhang B, et al. Refractory Hypertension: Definition, Prevalence, and Patient Characteristics. J Clin Hypertens. 2012;14:7–12.
17. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith Jr SC, Crowley K, et al. REACH Registry Investigators. Resistant Hypertension: A Frequent and Ominous Finding Among Hypertensive Patients with Atherothrombosis. Eur Heart J. 2013;34:1204–14.
18. Muiesan ML, Salvetti M, Rizzoni D, Paini A, Agabiti-Rosei C, Aggiusti C, et al. Resistant Hypertension and Target Organ Damage. Hypertens Res. 2013;36:485–91.
19. Calhoun DA, Booth 3rd JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, et al. Refractory Hypertension: Determination of Prevalence, Risk Factors, and Comorbidities in a Large, Population-Based Cohort. Hypertension. 2014;63:451–8. New definition of refractory hypertension as (uncontrolled office BP using > 5 anti-hypertensive drugs), focusing a very higher cardiovascular risk compared with others RHT patients.
20. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, et al. The Reasons for Geographic and Racial Differences in Stroke Study: Objectives and Design. Neuroepidemiology. 2005;25:135–43.
21. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients with Atherothrombosis. JAMA. 2006;295:180–9.
22. Parati G, Ochoa JE, Bilo G. Renal Sympathetic Denervation and Daily Life Blood Pressure in Resistant Hypertension: Simplicity or Complexity? Circulation. 2013;128:315–7.
23. de Souza F, Muxfeldt ES, Salles GF. Prognostic Factors in Resistant Hypertension: Implications for Cardiovascular Risk Stratification and Therapeutic Management. Expert Rev Cardiovasc Ther. 2012;10:735–45.
24. Salles G, Cardoso C, Nogueira AR, Bloch K, Muxfeldt E. Importance of the Electrocardiographic Strain Pattern in Patients with Resistant Hypertension. Hypertension. 2006;48:437–42.
25. Cuspidi C, Vaccarella A, Negri F, Sala C. Resistant Hypertension and Left Ventricular Hypertrophy: An Overview. J Am Soc Hypertens. 2010;4:319–24.
26. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for Chamber Quantification. Eur J Echocardiogr. 2006;7:79–108.
27. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S, et al. Left Ventricular Concentric Geometry During Treatment Adversely Affects Cardiovascular Prognosis in Hypertensive Patients. Hypertension. 2004;43:731–8.
28. Cuspidi C, Giudici V, Negri F, Sala C, Mancia G. Left Ventricular Geometry, Ambulatory Blood Pressure and Extra-Cardiac Organ Damage in Untreated Essential Hypertension. Blood Press Monit. 2010;15:124–31.
29. Salles GF, Fiszman R, Cardoso CR, Muxfeldt ES. Relation of Left Ventricular Hypertrophy with Systemic Inflammation and Endothelial Damage in Resistant Hypertension. Hypertension. 2007;50:723–8.
30. Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES. Prognostic Impact of Baseline and Serial Changes in ECG Left Ventricular Hypertrophy in Resistant Hypertension. Am Heart J. 2010;159:833–40. The prognostic importance of baseline and serial changes of left ventricular hypertrophy diagnosed by ECG. Treatment targeted at regression/prevention of LVH may improve cardiovascular prognosis.
31. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical Features of 8295 Patients with Resistant Hypertension Classified on the Basis of Ambulatory Blood Pressure Monitoring. Hypertension. 2011;57:898–902. Based on Spanish Ambulatory Blood Pressure Monitoring Registry, this study estimated the prevalence of RHT (12.2%) and showed that true RHT is associated with a worse risk profile.
32. Salles G, Leocádio S, Bloch K, Nogueira AR, Muxfeldt E. Combined QT Interval and Voltage Criteria Improve Left Ventricular Hypertrophy Detection in Resistant Hypertension. Hypertension. 2005;46:1207–12.
33. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic Value of Ventricular Repolarization Prolongation in Resistant Hypertension: A Prospective Cohort Study. J Hypertens. 2009;27:1094–101.
34. Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES. Prognostic Significance of Baseline and Serial Changes in ECG Strain Pattern in Resistant Hypertension. J Hypertens. 2010;28:1715–23.
35. Schillaci G, Pasqualini L, Verdecchia P, Vaudo G, Marchesi S, Porcellati C, et al. Prognostic Significance of Left Ventricular Diastolic Dysfunction in Essential Hypertension. J Am Coll Cardiol. 2002;39:2005–11.
36. Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, et al. Rapid Reversal of Left Ventricular Hypertrophy and Intracardiac Volume Overload in Patients with Resistant Hypertension and Hyperaldosteronism: A Prospective Clinical Study. Hypertension. 2010;55:1137–42.
37. Pimenta E, Gordon RD, Ahmed AH, Cowley D, Leano R, Marwick TH, et al. Cardiac Dimensions Are Largely Determined by Dietary Salt in Patients with Primary Aldosteronism: Results of a Case-Control Study. J Clin Endocrinol Metab. 2011;96:2813–20.
38. Schmieder RE. The Role of non-Haemodynamic Factors of the Genesis of LVH. Nephrol Dial Transplant. 2005;20:2610–2.
39. Muxfeldt ES, Cardoso CRL, Salles GF. Prognostic Value of Nocturnal Blood Pressure Reduction in Resistant Hypertension. Arch Intern Med. 2009;169:874–80.
40. Smith SM, Gong Y, Handberg E, Messerli FH, Bakris GL, Ahmed A, et al. Predictors and Outcomes of Resistant Hypertension Among Patients with Coronary Artery Disease and Hypertension. J Hypertens. 2014;32:635–43.
41. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. INVEST Investigators. A Calcium Antagonist vs a non-Calcium Antagonist Hypertension Treatment Strategy for Patients with Coronary Artery Disease. The International Verapamil-Trandolapril Study (INVEST): a Randomized Controlled Trial. JAMA. 2003;290:2805–16.
42. Bangalore S, Fayyad R, Laskey R, Demicco DA, Deedwania P, Kostis JB, et al. Treating to New Targets Steering Committee and Investigators. Prevalence, Predictors, and Outcomes in Treatment-Resistant Hypertension in Patients with Coronary Disease. Am J Med. 2014;127:71–81.
43. Faraco G, Iadecola C. Hypertension: A Harbinger of Stroke and Dementia. Hypertension. 2013;62:810–7.
44. Zanchetti A, Hennig M, Hollweck R, Bond G, Tang R, Cuspidi C, et al. Baseline Values but not Treatment-Induced Changes in Carotid Intima-Media Thickness Predict Incident Cardiovascular Events in Treated Hypertensive Patients: Findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation. 2009;120:1084–90.
45. Schmieder RE, Schmidt BM, Raff U, Bramlage P, Dörfler A, Achenbach S, et al. Cerebral Microangiopathy in Treatment-Resistant Hypertension. J Clin Hypertens. 2011;13:582–7.
46. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of Cardiovascular Events and all-Cause Mortality with Arterial Stiffness: A Systematic Review and Meta-Analysis. J Am Coll Cardiol. 2010;55:1318–27.
47. Castelpoggi CH, Pereira VS, Fiszman R, Cardoso CRL, Muxfeldt ES, Salles G. A Blunted Decrease in Nocturnal Blood Pressure is Independently Associated with Increased Aortic Stiffness in Patients with Resistant Hypertension. Hypertens Res. 2009;32:591–6.
48. Muxfeldt ES, de Souza F, Salles GF. Resistant Hypertension: A Practical Clinical Approach. J Hum Hypert. 2013;27:657–2.
49. Salles GF, Cardoso CRL, Fiszman R, Muxfeldt ES. Prognostic Importance of Baseline and Serial Changes in Microalbuminuria in Patients with Resistant Hypertension. Atherosclerosis. 2011;216:199–204. Baseline microalbuminuria is an important predictor of cardiovascular morbidity and mortality and microalbuminuria regression may be a antihypertensive treatment target.
50. Muxfeldt ES, Bloch KV, Nogueira AR, Salles GF. True Resistant Hypertension: Is it Possible to be Recognized in the Office? Am J Hypert. 2005;18:1534–40.
51. Oliveras A, Armario P, Martell-Clarós N, Ruilope LM, de la Sierra A, Spanish Society of Hypertension-Resistant Hypertension Registry. Urinary Albumin Excretion Is Associated with Nocturnal Systolic Blood Pressure in Resistant Hypertensives. Hypertension. 2011;57:556–60.
52. Oliveras A, Armario P, Sierra C, Arroyo JA, Hernández-del-Rey R, Vazquez S, et al. Urinary Albumin Excretion at Follow-up Predicts Cardiovascular Outcomes in Subjects with Resistant Hypertension. Am J Hypertension. 2013;26:1148–54. Inability to regression, persistence and new appearance of urinary albumin excretion were associated with non-fatal cardiovascular events and death, whereas baseline albuminuria had no prognostic value.
53. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, et al. Relation of Dietary Salt and Aldosterone to Urinary Protein Excretion in Subjects with Resistant Hypertension. Hypertension. 2008;51:339–44.
54. Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutiérrez OM, Irvin MR, et al. Incident ESRD and Treatment-Resistant Hypertension: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Kidney Dis. 2013. doi:10.1053/j.ajkd.2013.11.016.
55. Salles GF, Cardoso CR, Pereira VS, Fiszman R, Muxfeldt ES. Prognostic Significance of a Reduced Glomerular Filtration Rate and Interaction with Microalbuminuria in Resistant Hypertension: A Cohort Study. J Hypertens. 2011;29:2014–23. Reduced glomerular filtration rate combined with increased albuminuria identifies a very high cardiovascular risk in patients with RHT.
56. Drexler YR, Bomback AS. Definition, Identification and Treatment of Resistant Hypertension in Chronic Kidney Disease Patients. Nephrol Dial Transplant 2013 (Epub ahead of print).